Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Research & Development (2023 - 2026)

Compass Therapeutics' Research & Development history spans 4 years, with the latest figure at $13.4 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 2.57% to $13.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $56.3 million, a 22.72% increase, with the full-year FY2025 number at $56.0 million, up 32.18% from a year prior.
  • Research & Development hit $13.4 million in Q1 2026 for Compass Therapeutics, down from $13.7 million in the prior quarter.
  • Over the last five years, Research & Development for CMPX hit a ceiling of $16.4 million in Q2 2025 and a floor of $6.6 million in Q1 2023.
  • Historically, Research & Development has averaged $11.5 million across 4 years, with a median of $12.4 million in 2023.
  • Biggest five-year swings in Research & Development: fell 2.48% in 2024 and later soared 48.93% in 2025.
  • Tracing CMPX's Research & Development over 4 years: stood at $12.4 million in 2023, then increased by 4.93% to $13.0 million in 2024, then increased by 4.86% to $13.7 million in 2025, then decreased by 2.06% to $13.4 million in 2026.
  • Business Quant data shows Research & Development for CMPX at $13.4 million in Q1 2026, $13.7 million in Q4 2025, and $12.8 million in Q3 2025.